Interviews

July 22, 2022

Introduction to Mike Thompson MBE

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

June 29, 2022

Fungi, Mycelium and Mycology with Dr. Jonathan Curry

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

June 8, 2022

How might psilocybin change the way we treat mental health and cancer-related distress?

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

May 26, 2022

Introducing Dr. Sara Tai

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

May 16, 2022

Albert Labs approved by Health Canada for psilocybin possession, production and delivery license

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

May 12, 2022

Albert Labs announces partnership with drug safety & toxicology experts at the University of CESPU

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

April 28, 2022

Albert Labs adds natural drug development expert Prof. Rob Britton to its scientific advisory team

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

April 28, 2022

Albert Labs adds toxicology expert Dr. Ricardo Dinis-Oliveira to its scientific advisory team

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

April 14, 2022

Imperial College study on psilocybin for depression highlights need for Real-World Evidence trials

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

April 5, 2022

Albert Labs files provisional patent in the US for its Psilocybe mycelia cultivation process

Albert Labs, today announced that it has received conditional approval for the listing of its…

Albert Labs

Love0

Interviews

Introduction to Mike Thompson MBE

Fungi, Mycelium and Mycology with Dr. Jonathan Curry

How might psilocybin change the way we treat mental health and cancer-related distress?

Introducing Dr. Sara Tai

Albert Labs approved by Health Canada for psilocybin possession, production and delivery license

Albert Labs announces partnership with drug safety & toxicology experts at the University of CESPU

Albert Labs adds natural drug development expert Prof. Rob Britton to its scientific advisory team

Albert Labs adds toxicology expert Dr. Ricardo Dinis-Oliveira to its scientific advisory team

Imperial College study on psilocybin for depression highlights need for Real-World Evidence trials

Albert Labs files provisional patent in the US for its Psilocybe mycelia cultivation process

Innovative mental health medicines for patients with unmet needs.

Navigate

About

Team

News

Contact

Connect

info@albertlabs.com

Get in touch

About Salient